Ísrael - hebreska - Ministry of Health

dexcel ltd, israel - ciclosporin - קפסולות - ciclosporin 50 mg - cyclosporin - cyclosporin - prophylaxis of organ rejection in kidney, liver, heart allogenic transplants in conjunction with corticosteroids. may also be used in the treatment of chronic rejections in patients previously treated with other immunosuppresive agents. bone marrow transplantation. endogenous uveitis. severe psoriasis above age 16 that does not respond to other treatment . atopic dermatitis in adults only up to 8 weeks, for severe cases in which conventional therapy is ineffective or inappropriate. rheumatoid arthritis, severe cases when standard treatment is ineffective or inappropriate. nephrotic syndrome type mcd (minimal change disease) in cases where conventional therapy has failed.

Ísrael - hebreska - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Ísrael - hebreska - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 10 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Ísrael - hebreska - Ministry of Health

novartis israel ltd - everolimus - טבליה - everolimus 2.5 mg - everolimus - everolimus - * treatment of patients with advanced renal cell carcinoma after failure of treatment with sunitinib or sorafenib.* for the treatment of patients with sega associated with tuberous sclerosis (ts) who require therapeutic intervention but are not candidates for curative surgical resection.the effectiveness of afinitor is based on an analysis of change in sega volume. clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been demonstrated.* treatment of progressive neuroendocrine tumors of pancreatic origin (pnet) in patients with unresectable, locally advanced or metastatic disease.the safety and effectiveness of afinitor® in the treatment of patients with carcinoid tumors have not been established.* for the treatment of hormone receptor – positive, her2/neu negative advanced breast cancer, in combination with exemestane, in postmenopausal women without symptomatic visceral disease after recurrence of progression follwing a non – steroidal aromatase inhibitor.*

Ísrael - hebreska - Ministry of Health

cts ltd - ferric carboxymaltose - תמיסה להזרקה\אינפוזיה - ferric carboxymaltose 1800 mg/vial - ferinject is indicated for treatment of iron deficiency when oral iron preparations are ineffective or cannot be used. the diagnosis must be based on laboratory tests.

Ísrael - hebreska - Ministry of Health

padagis israel agencies ltd, israel - glyceryl trinitrate - משחה - glyceryl trinitrate 0.4 % - glyceryl trinitrate - glyceryl trinitrate - for relief of pain associated with chronic anal fissure. in the clinical development of the drug a modest effect has shown on improvement in average daily pain intensity.

Ísrael - hebreska - Ministry of Health

neopharm ltd - polidocanol; soya oil - תמיסה - soya oil 82.95 g / 100 g; polidocanol 15 g / 100 g - polidocanol - polidocanol - refatting medical oil bath with antipruritic effect.

Ísrael - hebreska - Ministry of Health

pfizer pfe pharmaceuticals israel ltd - medroxyprogesterone acetate - תרחיף להזרקה - medroxyprogesterone acetate 104 mg / 0.65 ml - medroxyprogesterone - medroxyprogesterone - * sayana is indicated for long-term female contraception. each subcutaneous injection prevents ovulation and provides contraception for at least 13 weeks (+/- 1 week). however, it should be taken into consideration that the return to fertility (ovulation) may be delayed for up to one year .since loss of bone mineral density may occur in females of all ages who use sayana long-term, a risk/benefit assessment, which also takes into consideration the decrease in bone mineral density that occurs during pregnancy and/or lactation, should be considered.* use in adolescents (12-18 years)in adolescents, use of sayana is only indicated when other contraceptive methods are considered unsuitable or unacceptable, due to unknown long-term effects of bone loss associated with sayana during the critical period of bone accretion.sayana has not been studied in women under the age of 18 years but data is available for intramuscular medroxyprogesterone acetate in this population.

Ísrael - hebreska - Ministry of Health

glaxo smith kline (israel) ltd - aciclovir - תרחיף - aciclovir 200 mg / 5 ml - aciclovir - aciclovir - zovirax oral presentations are indicated for the treatment of herpes simplex virus infections of the skin and mucous membranes including initial and recurrent genital herpes, for the suppression (prevention of recurrences) of recurrent herpes simplex infections in immune-competent patients, for the prophylaxis of herpes simplex infections in immune-compromised patients and for the treatment of herpes zoster (shingles) infections. studies have shown that early treatment of shingles with zovirax has a beneficial effect on pain and can reduce the incidence of post-herpetic neuralgia (zoster associated pain). zovirax oral presentations should be considered for the treatment of chickenpox in certain groups at increased risk of severe varicella or its complications. these groups are as follows: 1. non-pregnant patients over 13 years-of-age who are otherwise healthy. 2. children over 12 months of age with a chronic cutaneous or pulmonary condition, or receiving long-term salicylate therapy. 3. children receiving sho

Ísrael - hebreska - Ministry of Health

padagis israel agencies ltd, israel - azathioprine - טבליות מצופות פילם - azathioprine 25 mg - azathioprine - azathioprine - immunosuppressive agent used in transplantation surgery for suppression of graft rejection. for special cases of rheumatoid arthritis- not responsive to other agents- and only by rheumatology experts in hospitals or rheumatic clinics.